Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of mitoxantrone hydrochloride liposome injection in relapsed/refractory diffuse large B-cell lymphoma
CTR20231328Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone in diffuse large B-cell lymphoma (DLBCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Aug 2023; status: active.
02
Drugs
mitoxantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20231328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231328.